莫西沙星与亚胺培南西司他丁钠治疗流感后继发细菌性肺炎的效果对比

Comparison of Moxifloxacin and Imipenem-cilastatin Sodium in the Treatment of Bacterial Pneumonia Secondary to Influenza

目的:探讨莫西沙星对比亚胺培南西司他丁钠治疗流感后继发细菌性肺炎的效果。方法:使用数字双盲法将2019年1-12月在本院接受治疗的100例流感后继发细菌性肺炎患者分为两组,观察组口服莫西沙星400 mg,1次/d。对照组静脉滴注亚胺培南西司他丁钠,500 mg,每8小时1次,对比两组治疗效果、血气水平、炎性指标、治疗成本。结果:观察组总有效率(92.0%)优于对照组(76.0%),差异有统计学意义(P<0.05),两组PaO2、SaO2、PaO2/FiO2等血气指数指标和PCT、CRP等炎性因子水平差异无统计学意义(P>0.05),观察组治疗费用及效果-成本比值均低于对照组,差异有统计学意义(P<0.05)。结论:流感后继发的细菌性肺炎治疗中莫西沙星、亚胺培南西司他丁钠均可起到改善血气水平,降低炎性指标的效果,但是莫西沙星治疗效果更为理想,更加经济,实施价值更大,值得临床应用与推广。

Objective:To explore the therapeutic effect of Moxifloxacin and Imipenem-cilastatin sodium on bacterial pneumonia secondary to influenza.Method:A total of 100 cases of bacterial pneumonia secondary to influenza in our hospital from January to December 2019 were divided into two groups by digital double-blind method.The observation group was treated with Moxifloxacin 400 mg,qd.The control group was treated with Imipenem-cilastatin Sodium 500 mg,q8h.The therapeutic effect,blood gas level,inflammatory index and cost of the two groups were compared.Result:The total effective rate of the observation group (92.0%) was better than that of the control group (76.0%),with statistical difference (P<0.05).There was no difference in PaO2,SaO2,PaO2/FiO2 and inflammatory factors such as PCT and CRP between the two groups (P>0.05).The treatment cost and effect cost ratio of the observation group were lower than that of the control group,with statistical difference (P<0.05).Conclusion:Moxifloxacin and Imipenem-cilastatin Sodium can improve the blood gas level and reduce the inflammatory index in the treatment of bacterial pneumonia secondary to influenza,but Moxifloxacin is more ideal,more economical,more valuable and worthy of clinical application and promotion.